Literature DB >> 11300671

A comparison of two opioid analgesics for relief of visceral pain induced by intestinal resection in rats.

M B Gillingham1, M D Clark, E M Dahly, L A Krugner-Higby, D M Ney.   

Abstract

While developing a rat model for human short bowel syndrome, we noted that untreated rats as well as rats administered buprenorphine after intestinal resection exhibited behavior and appearance consistent with visceral pain and distress. To provide appropriate analgesics, we developed criteria to assess pain-related behavioral changes and conducted an experiment to evaluate the effectiveness of buprenorphine versus oxymorphone to alleviate the pain induced by intestinal resection. Rats underwent either small-bowel resection or transection surgery; in addition, animals received jugular catheterization for the delivery of total parenteral nutrition (TPN). Rats treated with buprenorphine received 0.5 mg/kg every 6 h subcutaneously, and rats treated with oxymorphone received 0.03 mg/kg hourly for 32 h via continuous intravenous (i.v.) infusion with TPN solution. Rats treated with buprenorphine exhibited behavior and appearance consistent with pain and distress for as long as 32 h postoperatively, whereas animals treated with oxymorphone exhibited behavior and appearance similar to their preoperative state. Thus, oxymorphone alleviated the pain-related behavioral changes after intestinal resection far better than did buprenorphine. Of interest, we observed that the buprenorphine was associated with a decrease in the volume of urine collected, whereas oxymorphone was associated with urine volumes similar to those of nonresected rats maintained with TPN. Because oxymorphone appeared to be a superior analgesic, we also evaluated three routes for administering this drug. Pain-related behavior changes were alleviated by the administration of oxymorphone by either Alzet mini-pump, bolus i.v. injection, or continuous i.v. infusion. We conclude that compared with buprenorphine, oxymorphone is a superior analgesic for the alleviation of visceral pain due to intestinal resection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300671

Source DB:  PubMed          Journal:  Contemp Top Lab Anim Sci        ISSN: 1060-0558


  6 in total

1.  Voluntary Running-Wheel Activity, Arterial Blood Gases, and Thermal Antinociception in Rats after 3 Buprenorphine Formulations.

Authors:  Rebecca A Johnson
Journal:  J Am Assoc Lab Anim Sci       Date:  2016       Impact factor: 1.232

2.  Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats.

Authors:  Patricia L Foley; Haixiang Liang; Andrew R Crichlow
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-03       Impact factor: 1.232

3.  Assessment of buprenorphine, carprofen, and their combination for postoperative analgesia in olive baboons (Papio anubis).

Authors:  Sarah O Allison; Lisa C Halliday; Jeffrey A French; Dmitri D Novikov; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2007-05       Impact factor: 1.232

4.  Evaluation of buprenorphine hydrochloride Pluronic(®) gel formulation in male C57BL/6NCrl mice.

Authors:  Terry L Blankenship-Paris; John W Dutton; David R Goulding; Christopher A McGee; Grace E Kissling; Page H Myers
Journal:  Lab Anim (NY)       Date:  2016-09-21       Impact factor: 12.625

5.  Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.

Authors:  Matthew C Koopmann; David W Nelson; Sangita G Murali; Xiaowen Liu; Mark S Brownfield; Jens J Holst; Denise M Ney
Journal:  JPEN J Parenter Enteral Nutr       Date:  2008 May-Jun       Impact factor: 4.016

6.  Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome.

Authors:  Matthew C Koopmann; Xiaowen Liu; Christopher J Boehler; Sangita G Murali; Jens J Holst; Denise M Ney
Journal:  JPEN J Parenter Enteral Nutr       Date:  2009-07-30       Impact factor: 4.016

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.